ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

NCT01086501 · clinicaltrials.gov ↗
COMPLETED
Status
225
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Desitin Arzneimittel GmbH